{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:23:46Z","timestamp":1778534626321,"version":"3.51.4"},"reference-count":147,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta and protects IgG from degradation. Numerous clinical trials are investigating therapeutic FcRn inhibition for various immune\u2010mediated neuromuscular and rheumatologic conditions; however, FcRn inhibition also represents a potential therapy for IgG\u2010mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, immune thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell\/platelet alloimmunization). Current evidence derived from both in vitro and in vivo studies suggests that FcRn inhibitors effectively reduce total IgG levels without impacting its production or altering the levels of other immunoglobulin isotypes. Moreover, the risk of serious adverse events, including serious infections, appears to be lower than that seen with other commonly used immunomodulatory\/immunosuppressive therapies, albeit in the setting of limited clinical trial data. Ultimately, additional clinical trials that include varied patient populations are required prior to incorporating these agents into standard treatment algorithms for most hematologic conditions. However, based on the pathophysiology of IgG\u2010mediated hematologic disorders and the mechanism of action of FcRn inhibitors, these agents may represent a future novel therapeutic strategy for patients with hematologic conditions caused by IgG antibodies.<\/jats:p>","DOI":"10.1002\/ajh.27487","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T12:07:14Z","timestamp":1727352434000},"page":"2351-2366","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions"],"prefix":"10.1002","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-9685","authenticated-orcid":false,"given":"Jeremy W.","family":"Jacobs","sequence":"first","affiliation":[{"name":"Division of Transfusion Medicine, Department of Pathology, Microbiology, &amp; Immunology Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8422-9480","authenticated-orcid":false,"given":"Garrett S.","family":"Booth","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Department of Pathology, Microbiology, &amp; Immunology Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheharyar","family":"Raza","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Pathobiology University of Toronto  Toronto Ontario Canada"},{"name":"Canadian Blood Services Medical Affairs and Innovation  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Landon M.","family":"Clark","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine  Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8877-956X","authenticated-orcid":false,"given":"Ross M.","family":"Fasano","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Center for Transfusion and Cellular Therapy Emory University School of Medicine  Atlanta Georgia USA"},{"name":"Department of Pediatrics, Aflac Cancer and Blood Disorders Center Emory University School of Medicine  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-8208","authenticated-orcid":false,"given":"Eleni","family":"Gavriilaki","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit G. Papanicolaou Hospital  Thessaloniki Greece"},{"name":"2nd Propedeutic Department of Internal Medicine Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5526-966X","authenticated-orcid":false,"given":"Elizabeth A.","family":"Abels","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Bridgeport Hospital\/Yale University  Bridgeport Connecticut USA"},{"name":"Department of Laboratory Medicine Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1246-8957","authenticated-orcid":false,"given":"Thomas C.","family":"Binns","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam Andrea","family":"Duque","sequence":"additional","affiliation":[{"name":"Department of Pathology University of Miami Miller School of Medicine  Miami Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-7185","authenticated-orcid":false,"given":"Zoe K.","family":"McQuilten","sequence":"additional","affiliation":[{"name":"Department of Haematology Monash Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9083-855X","authenticated-orcid":false,"given":"Mar\u00eda Eva","family":"Mingot\u2010Castellano","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda Hospital Universitario Virgen del Roc\u00edo, Instituto de Biomedicina de Sevilla  Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6437-5296","authenticated-orcid":false,"given":"Deva","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Department of Pathology, Microbiology, &amp; Immunology Vanderbilt University Medical Center  Nashville Tennessee USA"},{"name":"Division of Hematology\/Oncology, Department of Medicine Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9974-5277","authenticated-orcid":false,"given":"Minh\u2010Ha","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine University of California, Irvine  Irvine California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-2245","authenticated-orcid":false,"given":"Christopher A.","family":"Tormey","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Kenneth J.","family":"Moise","sequence":"additional","affiliation":[{"name":"Department of Women's Health Dell Medical School\u2010University of Texas at Austin  Austin Texas USA"},{"name":"Comprehensive Fetal Care Center Dell Children's Medical Center  Austin Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan M.","family":"Bloch","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Department of Pathology Johns Hopkins School of Medicine  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-2762","authenticated-orcid":false,"given":"Brian D.","family":"Adkins","sequence":"additional","affiliation":[{"name":"Department of Pathology University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469\u2010185X.1958.tb01412.x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830150718"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1403014"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577\u2010022\u201000821\u20101"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01540"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.024"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxg018"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.7.3528"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474\u20104422(21)00159\u20109"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010022\u201001678\u20103"},{"key":"e_1_2_11_14_1","unstructured":"US FDA.FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. [Accessed July 1 2024].https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-chronic-inflammatory-demyelinating-polyneuropathy-cidp-adults."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)01460\u20105"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673\u20105374.363824"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201003\u2010754119"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1810479"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231172831"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005555"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8737"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6020016"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003599"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012541"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19078"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.098921"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201010\u2010605493"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201008\u2010302984"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010019\u201002790\u2010z"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2021.103246"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0955\u20103886(98)00044\u20107"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423\u20100410.1983.tb01905.x"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.22000"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.22043"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27448"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1143"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25680"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002003"},{"key":"e_1_2_11_39_1","unstructured":"ClinicalTrials.gov (NCT04200456).A study to evaluate the efficacy safety and tolerability of rozanolixizumab in adult study participants with persistent or chronic primary immune thrombocytopenia (ITP) (myOpportunITy1). [Accessed July 2 2024].https:\/\/clinicaltrials.gov\/study\/NCT04200456?cond=NCT04200456&rank=1."},{"key":"e_1_2_11_40_1","unstructured":"ClinicalTrials.gov (NCT04224688).A study to assess the efficacy safety and tolerability of rozanolixizumab in adult study participants with persistent or chronic primary immune thrombocytopenia (ITP) (myOpportunITy2). [Accessed July 2 2024].https:\/\/clinicaltrials.gov\/study\/NCT04224688?cond=NCT04224688&rank=1."},{"key":"e_1_2_11_41_1","unstructured":"ClinicalTrials.gov (NCT04596995).A study to investigate the long\u2010term safety tolerability and efficacy of rozanolixizumab in study participants with persistent or chronic primary immune thrombocytopenia (ITP) (myOpportunITy3). [Accessed July 2 2024].https:\/\/clinicaltrials.gov\/study\/NCT04596995."},{"key":"e_1_2_11_42_1","unstructured":"Patient Centered Outcomes Research Institute.Rozanolixizumab (UCB7665) to treat primary immune thrombocytopenia. [Accessed June 16 2024].https:\/\/horizonscandb.pcori.org\/report\/topics\/531."},{"key":"e_1_2_11_43_1","unstructured":"ClinicalTrials.gov (NCT04225156).A long\u2010term study to assess the safety and efficacy of Efgartigimod in adult patients with primary immune thrombocytopenia (ITP). (ADVANCE+). [Accessed July 2 2024].https:\/\/clinicaltrials.gov\/study\/NCT04225156?cond=NCT04225156&rank=1."},{"key":"e_1_2_11_44_1","unstructured":"ClinicalTrials.gov (NCT04812925).A phase 3 study to evaluate the safety and efficacy of Efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia (ADVANCE SC+). [Accessed July 2 2024].https:\/\/clinicaltrials.gov\/study\/NCT04812925."},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2033982"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102016.1.690"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2012.01.002"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9586"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.016"},{"key":"e_1_2_11_50_1","unstructured":"ClinicalTrials.gov (NCT03075878).A safety study of SYNT001 in participants with warm autoimmune hemolytic anemia (WAIHA). [Accessed June 29 2024].https:\/\/clinicaltrials.gov\/study\/NCT03075878."},{"key":"e_1_2_11_51_1","unstructured":"ClinicalTrials.gov (NCT04956276).Subcutaneous ALXN1830 in adult participants with warm autoimmune hemolytic anemia. [Accessed June 29 2024].https:\/\/clinicaltrials.gov\/study\/NCT04956276."},{"key":"e_1_2_11_52_1","unstructured":"ClinicalTrials.gov (NCT04256148).ALXN1830 in patients with warm autoimmune hemolytic anemia. [Accessed June 29 2024].https:\/\/clinicaltrials.gov\/study\/NCT04256148."},{"key":"e_1_2_11_53_1","unstructured":"ClinicalTrials.gov (NCT04253236).To assess the efficacy and safety of RVT\u20101401 in the treatment of warm autoimmune hemolytic anemia (ASCEND\u2010WAIHA). (ASCEND\u2010WAIHA). [Accessed June 29 2024].https:\/\/clinicaltrials.gov\/study\/NCT04253236."},{"key":"e_1_2_11_54_1","unstructured":"ClinicalTrials.gov (NCT04119050).Efficacy and safety of M281 in adults with warm autoimmune hemolytic anemia (ENERGY) [Accessed July 1 2024].https:\/\/www.clinicaltrials.gov\/study\/NCT04119050?cond=NCT04119050&rank=1."},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010165585"},{"key":"e_1_2_11_56_1","unstructured":"ClinicalTrials.gov (NCT05221619).Post\u2010trial access for nipocalimab in participants with warm autoimmune hemolytic anemia (wAIHA). [Accessed July 2 2024].https:\/\/www.clinicaltrials.gov\/study\/NCT05221619?cond=NCT05221619&rank=1."},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102009.1.73"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009516"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2019-100"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27190"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201010\u2010709857"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(16)30018\u20107"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102015.1.631"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201011\u2010884700"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1813013"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(16)30125\u20109"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014514"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201011\u2010551580"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008443"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009150"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18192"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1213206"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005124"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239\u2010023\u201002768\u2010z"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201004\u2010840090"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1177\/1076029618825309"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12114"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201001\u2010550244"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017008268"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2022.09.001"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.11.030"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402567"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2023.150767"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.2450\/2015.0141\u201015"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12463"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100032\u20101305779"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.2147\/jbm.S342077"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.2147\/jbm.S284804"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.230771"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2016.11.030"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102721"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004957"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12700"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002977"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.2450\/2016.0030\u201016"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/hem.V19.2.2022214"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006315"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0002\u20109343(91)80140\u2010h"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102516.2002.00674.x"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102016.1.446"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000002912"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102015.1.146"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012241"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12265"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17342"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000137"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.027"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2376172"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201011\u2010327361"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.46989\/001c.94135"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001143"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133382"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1055473"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009283"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000499"},{"key":"e_1_2_11_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18825"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)01264\u20109"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24908"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1002\/uog.24891"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12884\u2010022\u201005329\u2010z"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471\u20100528.12063"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314466"},{"key":"e_1_2_11_123_1","unstructured":"Johnson & Johnson.Johnson & Johnson's nipocalimab granted U.S. FDA breakthrough therapy designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN). [Accessed June 24 2024].https:\/\/www.jnj.com\/media\u2010center\/press\u2010releases\/johnson\u2010johnsons\u2010nipocalimab\u2010granted\u2010u\u2010s\u2010fda\u2010breakthrough\u2010therapy\u2010designation\u2010for\u2010the\u2010treatment\u2010of\u2010individuals\u2010at\u2010high\u2010risk\u2010for\u2010severe\u2010hemolytic\u2010disease\u2010of\u2010the\u2010fetus\u2010and\u2010newborn\u2010hdfn."},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41591\u2010023\u201000024\u20108"},{"key":"e_1_2_11_125_1","unstructured":"MoiseKJ LingLE LoprioreE et al.Safety and efficacy of nipocalimab in early\u2010onset severe hemolytic disease of the fetus and newborn. Paper presented at: the Fetal Medicine Foundation World Congress (2023)."},{"key":"e_1_2_11_126_1","unstructured":"ClinicalTrials.gov (NCT05912517).A study of nipocalimab in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN) (AZALEA). [Accessed July 4 2024].https:\/\/www.clinicaltrials.gov\/study\/NCT05912517?cond=NCT05912517&rank=1."},{"key":"e_1_2_11_127_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013\u20103320"},{"key":"e_1_2_11_128_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018017"},{"key":"e_1_2_11_129_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471\u20100528.2010.02657.x"},{"key":"e_1_2_11_130_1","unstructured":"Johnson & Johnson.Johnson & Johnson's nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults. [Accessed June 24 2024].https:\/\/www.jnj.com\/media\u2010center\/press\u2010releases\/johnson\u2010johnsons\u2010nipocalimab\u2010granted\u2010u\u2010s\u2010fda\u2010fast\u2010track\u2010designation\u2010to\u2010reduce\u2010the\u2010risk\u2010of\u2010fetal\u2010neonatal\u2010alloimmune\u2010thrombocytopenia\u2010fnait\u2010in\u2010alloimmunized\u2010pregnant\u2010adults."},{"key":"e_1_2_11_131_1","unstructured":"ClinicalTrials.gov (NCT06449651).A study of nipocalimab in reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT) (FREESIA\u20101). [Accessed July 4 2024].https:\/\/clinicaltrials.gov\/study\/NCT06449651?cond=NCT06449651&rank=1."},{"key":"e_1_2_11_132_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201010\u2010739656"},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15216"},{"key":"e_1_2_11_134_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1346471"},{"key":"e_1_2_11_135_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01299"},{"key":"e_1_2_11_136_1","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmaa019"},{"key":"e_1_2_11_137_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201005\u2010647552"},{"key":"e_1_2_11_138_1","doi-asserted-by":"publisher","DOI":"10.1186\/2052\u20101839\u201013\u20104"},{"key":"e_1_2_11_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.118074"},{"key":"e_1_2_11_140_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci97911"},{"key":"e_1_2_11_141_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00682"},{"key":"e_1_2_11_142_1","unstructured":"US FDA.VYVGART\u2122 (Efgartigimod Alfa\u2010FCAB) injection for intravenous use. [Accessed June 24 2024].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761195s000lbl.pdf."},{"key":"e_1_2_11_143_1","unstructured":"Argenx.VYVGART\u00ae HYTRULO (efgartigimod alfa and hyaluronidase\u2010qvfc) injection for subcutaneous use. [Accessed June 24 2024].https:\/\/www.argenx.com\/product\/vyvgart-hytrulo-prescribing-information.pdf."},{"key":"e_1_2_11_144_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010023\u201001000\u2010z"},{"key":"e_1_2_11_145_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac608"},{"key":"e_1_2_11_146_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517720044"},{"key":"e_1_2_11_147_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21778"},{"key":"e_1_2_11_148_1","unstructured":"US FDA.FDA Adverse Event Reporting System (FAERS) Public Dashboard. [Accessed July 12 2024].https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.27487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T06:23:13Z","timestamp":1731392593000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.27487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":147,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/ajh.27487"],"URL":"https:\/\/doi.org\/10.1002\/ajh.27487","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"assertion":[{"value":"2024-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}